5-氯-2-硝基-4-(三氟甲基)苯胺 | 35375-74-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-2-硝基-4-(三氟甲基)苯胺
• 中文别名: 2-硝基-4-三氟甲基-5-氯苯胺；3-氯-6-硝基-4-三氟甲基苯胺；5-氯-2-硝基-4-三氟甲基苯胺
• 英文名称: 5-chloro-2-nitro-4-(trifluoromethyl)aniline
• 英文别名: 5-chloro-2-nitro-4-trifluoromethyl-phenylamine
• CAS: 35375-74-7
• 化学式: C₇H₄ClF₃N₂O₂
• mdl: MFCD01312277
• 分子量: 240.569
• InChiKey: AAMCWLIPRMIPBN-UHFFFAOYSA-N

物化性质

• 熔点：
  113 °C
• 沸点：
  310.7±42.0 °C(Predicted)
• 密度：
  1.614±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2921420090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  存储条件为室温、避光且在惰性气体环境中。

SDS

Name:	5-Chloro-2-nitro-4-(trifluoromethyl)aniline 97% Material Safety Data Sheet
Synonym:
CAS:	35375-74-7

Section 1 - Chemical Product MSDS Name:5-Chloro-2-nitro-4-(trifluoromethyl)aniline 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35375-74-7	5-Chloro-2-nitro-4-(trifluoromethyl)an	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35375-74-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 112 - 114 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H4ClF3N2O2
Molecular Weight: 241

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35375-74-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-2-nitro-4-(trifluoromethyl)aniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 35375-74-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 35375-74-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35375-74-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

5-氯-2-硝基-4-(三氟甲基)苯胺是一种具有较高应用价值的含氟芳香类有机化合物，是生产某些农药的关键中间体。含氟农药因其高选择性、高适性、高附加值、低成本、低毒性和低残留等特点，符合当代农药发展的趋势。近年来，国际上新开发的化学农药中约40%为含氟农药，然而我国生产的200多种农药品种中，含氟农药仅占8%左右，并且产量较低、品种单一，与世界先进农药技术差距较大。因此，氟化学品和含氟农药依然是人们研究的重点领域。

制备

我们以5-氯-2-硝基苯胺为原料，通过碘代、乙酰化保护、三氟甲基化及脱乙酰化四步反应，以较高收率制得了5-氯-2-硝基-4-(三氟甲基)苯胺中间体。在不断摸索过程中，我们发现三氟甲基化这一步的收率可达78%。5-氯-2-硝基-4-(三氟甲基)苯胺的合成主要包括：碘代、乙酰化保护、三氟甲基化和脱乙酰化四个步骤，合成路线如图1所示。

5-氯-2-硝基-4-(三氟甲基)苯胺合成路线图

通过以5-氯-2-硝基苯胺与单质碘为原料，经过碘代、乙酰化保护、三氟甲基化和脱乙酰化反应四步反应，最终合成了农药中间体5-氯-2-硝基-4-(三氟甲基)苯胺。该方法具有以下显著特点：① 原料廉价易得；② 反应条件温和、易于控制；③ 反应体系简单，中间体易于分离纯化；④ 单步收率高，总收率中等，具备潜在的开发应用价值。

反应信息

• 作为反应物：
  描述：

  5-氯-2-硝基-4-(三氟甲基)苯胺 在 tin(ll) chloride 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 0.58h， 生成 2-氨基-4-氯-5-三氟甲基苯胺
  参考文献：
  名称：

  取代的1,4-二氢喹喔啉-2,3-二酮的合成与构效关系：N-甲基-D-天冬氨酸（NMDA）受体甘氨酸位点和非NMDA谷氨酸受体的拮抗剂。

  摘要：

  合成了一系列的单，二，三和四取代的1,4-二氢喹喔啉-2,3-二酮（QXs），并在N-甲基-D-天冬氨酸（NMDA）/甘氨酸位点和α位作为拮抗剂进行了评估-氨基-3-羟基-5-甲基异恶唑-4-丙酸优先的非NMDA受体。通过电测定在表达大鼠全脑poly（A）+ RNA的非洲爪蟾卵母细胞中测量拮抗剂的效力。三取代QX 17a（ACEA 1021），17b（ACEA 1031），24a和27，在5位含硝基，在6和7位含卤素，在甘氨酸上显示出高效价（Kb约为6-8 nM）位点，对非NMDA受体的药效中等（Kb = 0.9-1.5 microM），与非NMDA受体相比，甘氨酸位点拮抗作用的选择性最高（120-250倍）。四取代的QX 17d e是比相应的三取代QX弱100倍的弱甘氨酸位点拮抗剂，在8位上F作为取代基比Cl具有更好的耐受性。与三取代类似物相比，二取代和单取代的QX显示出越来越弱的拮抗作

  DOI：

  10.1021/jm00022a003
• 作为产物：
  描述：

  N-[5-chloro-2-nitro-4-(trifluoromethyl)phenyl]acetamide 在 盐酸 作用下， 生成 5-氯-2-硝基-4-(三氟甲基)苯胺
  参考文献：
  名称：

  取代的1,4-二氢喹喔啉-2,3-二酮的合成与构效关系：N-甲基-D-天冬氨酸（NMDA）受体甘氨酸位点和非NMDA谷氨酸受体的拮抗剂。

  摘要：

  合成了一系列的单，二，三和四取代的1,4-二氢喹喔啉-2,3-二酮（QXs），并在N-甲基-D-天冬氨酸（NMDA）/甘氨酸位点和α位作为拮抗剂进行了评估-氨基-3-羟基-5-甲基异恶唑-4-丙酸优先的非NMDA受体。通过电测定在表达大鼠全脑poly（A）+ RNA的非洲爪蟾卵母细胞中测量拮抗剂的效力。三取代QX 17a（ACEA 1021），17b（ACEA 1031），24a和27，在5位含硝基，在6和7位含卤素，在甘氨酸上显示出高效价（Kb约为6-8 nM）位点，对非NMDA受体的药效中等（Kb = 0.9-1.5 microM），与非NMDA受体相比，甘氨酸位点拮抗作用的选择性最高（120-250倍）。四取代的QX 17d e是比相应的三取代QX弱100倍的弱甘氨酸位点拮抗剂，在8位上F作为取代基比Cl具有更好的耐受性。与三取代类似物相比，二取代和单取代的QX显示出越来越弱的拮抗作

  DOI：

  10.1021/jm00022a003

文献信息

• [EN] METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS (NAM) DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE ET UTILISATIONS DE CEUX-CI
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2015191630A1

  公开（公告）日：2015-12-17

  Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

  本文提供了小分子活性代谢型谷氨酸亚型-2和-3受体负向变构调节剂（NAMs），包括这些化合物的组合物，以及使用这些化合物和组合物的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• Quinoxaline derivatives useful in therapy
  申请人：Pfizer Inc.

  公开号：US05852016A1

  公开（公告）日：1998-12-22

  Compounds of formula (I), wherein A represents N or CH; R.sup.1 and R.sup.2 independently represent C.sup.1-4 alkyl, halo or CF.sub.3 ; R.sup.3 represents C.sub.1-4 alkyl (optionally substituted), C.sub.3-7 cycloalkyl, CF.sub.3 or aryl; R.sup.4 represents H, C.sub.3-7 cycloalkyl or C.sub.1-6 alkyl (optionally substituted); and their pharmaceutically acceptable derivatives; are useful in the treatment of, inter alia, neurodogenerative disorders. ##STR1##

  式（I）的化合物，其中A代表N或CH；R.sup.1和R.sup.2分别代表C.sup.1-4烷基，卤素或CF.sub.3；R.sup.3代表C.sub.1-4烷基（可选取代），C.sub.3-7环烷基，CF.sub.3或芳基；R.sup.4代表H，C.sub.3-7环烷基或C.sub.1-6烷基（可选取代）；以及它们的药学上可接受的衍生物；在治疗神经退行性疾病等方面是有用的。
• [EN] 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] DÉRIVÉS DE 2-AMINO-BENZIMIDAZOLE UTILES DANS LE TRAITEMENT D'INFLAMMATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076672A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I), their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the 10 treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R3, R4, R6, R2,R7, R8, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式（I）的化合物，它们作为微体前列腺素E2合酶-1（mPGES-1）的抑制剂的使用，包含它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病及相关状况的药物的使用。A、M、W、R1、R2、R3、R4、R6、R2、R7、R8、R9、Ra、Rb的含义在描述中给出。
• [1,2,4]triazolo[4,3-a]quinoxaline compounds
  申请人：Novo Nordisk A/S

  公开号：US05532236A1

  公开（公告）日：1996-07-02

  The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I ##STR1## wherein one of R.sup.1 and R.sup.2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C.sub.1-6 -alkyl, or one of R.sup.1 and R.sup.2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C.sub.1-6 -alkyl; and the other of R.sup.1 and R.sup.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, halogen, NO.sub.2, NH.sub.2, CN, CF.sub.3, COC.sub.1-6 -alkyl or SO.sub.2 NR'R", wherein R' and R" are independently hydrogen or C.sub.1-6 -alkyl; and X is O or S; and pharmaceutically acceptable salts thereof. The compounds have affinity for the AMPA receptors and are antagonists in connection with this type of receptors which makes them useful in the treatment of CNS ailments, especially in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids.

  本发明涉及式I的[1,2,4]三唑并[4,3-a]喹喔啉衍生物，其中R.sup.1和R.sup.2中的一个是5-或6-成员含氮杂环，可以选择性地用一个、两个或三个取代基取代，其中每个取代基独立地是苯基或C.sub.1-6-烷基，或者R.sup.1和R.sup.2中的一个是包括5-或6-成员含氮杂环和苯、吡啶、嘧啶或吡嗪环的融合环系统，其中融合环系统可以选择性地用苯基或C.sub.1-6-烷基取代；另一个是氢、C.sub.1-6-烷基、C.sub.1-6-烷氧基、卤素、NO.sub.2、NH.sub.2、CN、CF.sub.3、COC.sub.1-6-烷基或SO.sub.2NR'R"中的一个，其中R'和R"独立地是氢或C.sub.1-6-烷基；X是O或S；以及其药学上可接受的盐。这些化合物对AMPA受体具有亲和力，并且在与这种类型的受体有关的拮抗作用，使它们在治疗中枢神经系统疾病方面有用，特别是在治疗由兴奋性氨基酸过度活跃引起的众多症状的治疗中。